| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.11▼ | 4.16▼ | 4.16▼ | 4.42▼ | 3.14▲ |
| MA10 | 4.18▼ | 4.21▼ | 4.23▼ | 4.39▼ | 2.67▲ |
| MA20 | 4.24▼ | 4.30▼ | 4.38▼ | 3.41▲ | 2.30▲ |
| MA50 | 4.26▼ | 4.48▼ | 4.77▼ | 2.69▲ | 2.05▲ |
| MA100 | 4.37▼ | 5.02▼ | 3.93▲ | 2.28▲ | 2.97▲ |
| MA200 | 4.52▼ | 3.72▲ | 2.99▲ | 2.03▲ | 4.14▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.025▼ | -0.011▼ | -0.020▼ | 0.063▲ | 0.230▲ |
| RSI | 22.406▼ | 31.805▼ | 34.292▼ | 57.146▲ | 70.328▲ |
| STOCH | 5.498▼ | 33.830 | 21.689 | 20.950 | 34.926 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -82.225▼ | -78.551▼ |
| CCI | -139.467▼ | -151.478▼ | -139.780▼ | 6.840 | 137.830▲ |
|
Tuesday, October 21, 2025 12:11 PM
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.
|
|
Tuesday, October 21, 2025 06:55 AM
Minerva Neurosciences (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from neuropsychiatric disorders. With a primary ...
|
|
Tuesday, October 21, 2025 05:32 AM
Minerva Neurosciences ( NASDAQ: NERV) shares rose as much as 160% premarket on Tuesday after announcing financing of as much as $200 million and plans for NDA resubmission of its Schizophrenia drug.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/10/25 | 4.09 | 4.315 | 4.055 | 4.055 | 189,418 |
| 29/10/25 | 4.72 | 4.80 | 4.13 | 4.23 | 412,600 |
| 28/10/25 | 4.46 | 4.80 | 4.45 | 4.60 | 412,800 |
| 27/10/25 | 4.64 | 4.80 | 4.25 | 4.53 | 395,200 |
| 24/10/25 | 4.53 | 5.10 | 4.50 | 4.70 | 876,200 |
| 23/10/25 | 5.18 | 5.61 | 4.82 | 4.87 | 721,100 |
| 22/10/25 | 5.25 | 5.78 | 4.41 | 5.38 | 3,779,500 |
| 21/10/25 | 6.74 | 12.46 | 5.98 | 6.41 | 166,498,600 |
| 20/10/25 | 2.48 | 2.71 | 2.48 | 2.66 | 131,700 |
| 17/10/25 | 2.41 | 2.638 | 2.405 | 2.49 | 48,300 |
|
|
||||
|
|
||||
|
|